StoneX Group’s KALA BIO KALA Stock Holding History

StoneX Group’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-260	Closed	-$2.25K	–	1519
2026 Q1	$2.25K	Buy	260 +15	+6%	+$317	﹤0.01%	902
2025 Q4	$6.81K	Buy	+245	New	+$11K	﹤0.01%	1017
2022 Q4	–	Sell	-5	Closed	-$2.98K	–	736
2022 Q3	$2.98K	Buy	+5	New	+$3.93K	﹤0.01%	528

Other funds holding KALA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

StoneX Group's KALA Position: Q2 2026 in Review

StoneX Group sold out of KALA BIO (KALA) in Q2 2026, closing a stake of 260 shares — an estimated $2.25K sold.

StoneX Group first reported a position in KALA in Q3 2022 and held it in 3 quarters. The position peaked at $6.81K in Q4 2025. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.

StoneX Group reported no remaining KALA BIO position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 260 KALA BIO shares in Q2 2026, an estimated $2.25K.
StoneX Group first reported a position in KALA BIO in Q3 2022 and held it in 3 quarters.
StoneX Group's KALA BIO position peaked at $6.81K in Q4 2025.
14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.